Need to know the diffrence between r-chop & RICE... Is one more painful or is there a diffrence for treating re-occuring non hodkins lymphoma that is large b-cell & reoccured
Allison -
Information about the R-CHOP regimen can be found HERE. As you may know, CHOP, and now R-CHOP, is considered conventional chemotherapy treatment for large b cell lymphoma.
The "R-ICE" regimen consists of:
Rituximab
Ifosfamide
Carboplatin
Etoposide
Rituximab is the monoclonal antibody that is generally given to you first; there's information on rituximab (aka Rituxan, MabThera) on the above blog entry and elsewhere on this site.
Ifosfamide is an alkylating agent (i.e. how it kills cells) that has the potential to harm your bladder, so you're supposed to drink lots of liquids. Plus the drug mesna, which protects the bladder, is normally given along with the Ifosfamide.
Like Ifosfamide, carboplatin is an alkylating agent. It can reduce your white blood cell count even in the weeks after being administered, leaving the patient more prone to infections. Same is true with platelets, putting you at higher risk of bleeding problems.
Etoposide is derived from a plant and kills cells by inhibiting an enzyme from keeping DNA healthy. It has the same side-effects as the other two drugs, but etoposide presents an added, although rare, risk of developing a cancer like leukemia years down the road. The American Cancer Society says, "If you are getting this drug, your doctor feels this risk is outweighed by the risk of what might happen if you do not get this drug. You may want to discuss these risks with your doctor."
So the differences: R-CHOP features a steroid, prednisolone, and in my own opinion (based not on personal experience but on an understanding of the medications and the patient reports), the drugs used in R-CHOP—specifically the doxorubicin (hydoxydaunorubicin, the H) and the vincristine (Oncovin, the O), are particularly rough chemo drugs with really nasty potential side effects (keyword, potential—you won't necessarily experience them).
Right now, standard chemotherapy treatment for DLBCL is the R-CHOP regimen. If it fails, then doctors turn to R-ICE (or ESHAP, or DHAP, with or without rituximab added). I think this is why I had trouble finding clinical data comparing R-ICE to R-CHOP--because R-CHOP is considered the standard. I did find this very recent study, which compared R-ICE against R-DHAP and found no significant difference.
Bottom line, on paper R-ICE would seem to present fewer major side effects than R-CHOP but it may not be as effective a treatment.
The good news is that DLBCL is highly treatable and even curable with chemo.
Talk to your doctors about these drugs, and best of luck to you!
Ross
Hunt, Kristin E; Reichard, . "Diffuse Large B-Cell Lymphoma." Archives of Pathology & Laboratory Medicine. College of American Pathologists. 2008.
"Seattle Genetics Initiates SGN-40 Phase IIb Clinical Trial in Combination with Rituxan and Chemotherapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma." Business Wire. Business Wire. 2007.
Call 1-877-399-5078 Anytime To Discuss Treatment Options
If you or a loved one has been diagnosed with Lymphoma, please call toll-free 1-877-399-5078 for treatment options.
The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
More Information
SupportGroups.com
SupportGroups.com is for individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.
Since the early 1970s, incidence rates for non-Hodgkin’s lymphoma have nearly doubled. Improved diagnosis has contributed greatly to the increase as doctors better understand cancer of lymphocytes and can distinguish it from other diseases.
Need to know the diffrence between r-chop & RICE... Is one more painful or is there a diffrence for treating re-occuring non hodkins lymphoma that is large b-cell & reoccured
Allison -
Information about the R-CHOP regimen can be found HERE. As you may know, CHOP, and now R-CHOP, is considered conventional chemotherapy treatment for large b cell lymphoma.
The "R-ICE" regimen consists of:
Rituximab
Ifosfamide
Carboplatin
Etoposide
Rituximab is the monoclonal antibody that is generally given to you first; there's information on rituximab (aka Rituxan, MabThera) on the above blog entry and elsewhere on this site.
Ifosfamide is an alkylating agent (i.e. how it kills cells) that has the potential to harm your bladder, so you're supposed to drink lots of liquids. Plus the drug mesna, which protects the bladder, is normally given along with the Ifosfamide.
Like Ifosfamide, carboplatin is an alkylating agent. It can reduce your white blood cell count even in the weeks after being administered, leaving the patient more prone to infections. Same is true with platelets, putting you at higher risk of bleeding problems.
Etoposide is derived from a plant and kills cells by inhibiting an enzyme from keeping DNA healthy. It has the same side-effects as the other two drugs, but etoposide presents an added, although rare, risk of developing a cancer like leukemia years down the road. The American Cancer Society says, "If you are getting this drug, your doctor feels this risk is outweighed by the risk of what might happen if you do not get this drug. You may want to discuss these risks with your doctor."
So the differences: R-CHOP features a steroid, prednisolone, and in my own opinion (based not on personal experience but on an understanding of the medications and the patient reports), the drugs used in R-CHOP—specifically the doxorubicin (hydoxydaunorubicin, the H) and the vincristine (Oncovin, the O), are particularly rough chemo drugs with really nasty potential side effects (keyword, potential—you won't necessarily experience them).
Right now, standard chemotherapy treatment for DLBCL is the R-CHOP regimen. If it fails, then doctors turn to R-ICE (or ESHAP, or DHAP, with or without rituximab added). I think this is why I had trouble finding clinical data comparing R-ICE to R-CHOP--because R-CHOP is considered the standard. I did find this very recent study, which compared R-ICE against R-DHAP and found no significant difference.
Bottom line, on paper R-ICE would seem to present fewer major side effects than R-CHOP but it may not be as effective a treatment.
The good news is that DLBCL is highly treatable and even curable with chemo.
Talk to your doctors about these drugs, and best of luck to you!
Ross
Hunt, Kristin E; Reichard, . "Diffuse Large B-Cell Lymphoma." Archives of Pathology & Laboratory Medicine. College of American Pathologists. 2008.
"Seattle Genetics Initiates SGN-40 Phase IIb Clinical Trial in Combination with Rituxan and Chemotherapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma." Business Wire. Business Wire. 2007.